October 8, 2021 — Sponsors are challenged to keep track of complex sample inventories, both on study and for samples collected as part of completed studies that might be later mined for translational research needs. We frequently hear that teams spend significant time manually cross-referencing spreadsheets of inventory data, to answer questions such as:
- “How many whole blood samples with a particular mutation do we have across all phase I studies?”
- “Can we report sample expiration status across all of our contracted biorepositories?”
- “When we identify a sample of interest, how can we confirm consent status?”
